Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella GIM)

被引：4
|
作者：
Del Mastro, L. [1 ]
Poggio, F. [2 ]
Blondeaux, E. [3 ]
de Placido, S. [4 ]
Giuliano, M. [5 ]
De laurentiis, M. [6 ]
Bisagni, G. [7 ]
Cantore, M. [8 ]
Turletti, A. [9 ]
Nistico, C. [10 ]
Urracci, Y. [11 ]
Garrone, O. [12 ]
Bighin, C. [13 ]
Mansutti, M. [14 ]
Montemurro, F. [15 ]
Colantuoni, G. [16 ]
Lambertini, M. [1 ]
Boni, L. [3 ]
机构：
[1] IRCCS Osped Policlin San Martino, Internal Med Dept, Genoa, Italy
[2] IRCCS Osped Policlin San Martino, Med Oncol Dept, Genoa, Italy
[3] IRCCS Osped Policlin San Martino, Epidemiol Unit, Genoa, Italy
[4] Azienda Osped Univ Federico II, Dept Clin Med & Surg, Naples, Italy
[5] Univ Federico II, Dept Clin Med & Surg, Naples, Italy
[6] Ist Nazl Tumori IRCCS Fdn Pascale, Dept Breast & Thorac Oncol, Naples, Italy
[7] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, Med Oncol Dept, Reggio Emilia, Italy
[8] Azienda Osped Carlo Poma, Med Oncol, Mantua, Italy
[9] POEV ASL TO1, Med Oncol, Turin, Italy
[10] IRCCS Regina Elena Natl Canc Inst IRE, Oncol, Rome, Italy
[11] Osped Oncol A Businco, Med Oncol, Cagliari, Italy
[12] Osped Maggiore Policlin Fdn IRCCS Ca Granda, Med Oncol, Milan, Italy
[13] IRCCS Osped Policlin San Martino, Med Oncol 2, Genoa, Italy
[14] ASU Friuli Cent Osped S Maria Misericordia, Oncol Dept, Udine, Italy
[15] IRCCS Ist Candiolo FPO, Invest Clin Oncol Dept, Candiolo, TO, Italy
[16] Azienda Osped S Giuseppe Moscati, Haematol Oncol Dept, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.169
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
134O
引用
收藏
页码：S599 / S600
页数：2
相关论文
共 50 条
  • [21] Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
    S Kümmel
    J Krocker
    A Kohls
    G-P Breitbach
    G Morack
    M Budner
    J-U Blohmer
    D Elling
    [J]. British Journal of Cancer, 2006, 94 : 1237 - 1244
  • [22] Randomised trial:: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
    Kümmel, S
    Krocker, J
    Kohls, A
    Breitbach, GP
    Morack, G
    Budner, M
    Blohmer, JU
    Elling, D
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1237 - 1244
  • [23] Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer patients in a randomised trial.
    Kummel, S.
    Krocker, J.
    Kohls, A.
    Breitbach, G-P
    Budner, M.
    Keil, E.
    Hinke, A.
    Blohmer, J-U
    Elling, D.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S113 - S113
  • [24] Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial
    Morganti, Stefania
    Tolaney, Sara M.
    [J]. LANCET ONCOLOGY, 2022, 23 (12): : 1482 - 1484
  • [25] A phase III randomised trial comparing the tolerability of dose-dense chemotherapy in older to that in younger breast cancer patients with four or more positive lymph
    Kuemmel, S
    Krocker, J
    Kohls, A
    Budner, M
    Breitbach, GP
    Ruhland, K
    Köhler, U
    Reischauer, B
    Blohmer, JU
    Elling, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 24S - 24S
  • [26] A nonrandomized phase II study of dose-dense paclitaxel and cyclophosphamide (PC) in early-stage breast cancer (EBC)
    Ramaekers, Ryan C.
    Copur, Mehmet Sitki
    Cowan, Kenneth H.
    Mailliard, Mary
    Lyden, Elizabeth
    Razaq, Wajeeha
    Reed, Elizabeth C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer
    Burdette-Radoux, Susan
    Wood, Marie E.
    Olin, Julie J.
    Laughlin, Rebecca S.
    Crocker, Abigail M.
    Ashikaga, Takamaru
    Muss, Hyman B.
    [J]. BREAST JOURNAL, 2007, 13 (03): : 274 - 280
  • [28] Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer
    Zellars, Richard C.
    Stearns, Vered
    Frassica, Deborah
    Asrari, Fariba
    Tsangaris, Theodore
    Myers, Lee
    DiPasquale, Shirley
    Lange, Julie R.
    Jacobs, Lisa K.
    Emens, Leisha A.
    Armstrong, Deborah K.
    Fetting, John H.
    Garrett-Mayer, Elizabeth
    Davidson, Nancy E.
    Wolff, Antonio C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2816 - 2822
  • [29] Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a phase 2, single-arm feasibility study
    Traina, T. A.
    Hudis, C.
    Fornier, M.
    Lake, D.
    Lehman, R.
    Berkowitz, A. P.
    Rege, J.
    Liao, J.
    Cox, D.
    Seidman, A. D.
    [J]. CANCER RESEARCH, 2012, 72
  • [30] Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
    Lambertini, Matteo
    Poggio, Francesca
    Bruzzone, Marco
    Conte, Benedetta
    Bighin, Claudia
    de Azambuja, Evandro
    Giuliano, Mario
    De Laurentiis, Michele
    Cognetti, Francesco
    Fabi, Alessandra
    Bisagni, Giancarlo
    Durando, Antonio
    Turletti, Anna
    Urracci, Ylenia
    Garrone, Ornella
    Puglisi, Fabio
    Montemurro, Filippo
    Ceppi, Marcello
    Del Mastro, Lucia
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 160 - 169
12345